Skip to Main Content

Chronic Kidney Disease in Children


Progression of chronic kidney disease (CKD) in children leads to end stage kidney disease (ESKD), which is associated with mortality rates 30-150 times higher than the general pediatric population. The traditional biomarkers, serum creatinine and proteinuria, are used to predict progression of CKD in clinical trials even though both correlate poorly with the progression of CKD and the response to interventions.

We aim to identify the optimal combination of novel biomarkers which best predict progression of CKD in children. We plan to measure urine and blood biomarkers of kidney injury, inflammation, repair, and fibrosis from the samples of the children enrolled in the CKD in Children (CKiD) cohort and Assessment, Serial Evaluation, and Subsequent Sequelae in AKI (ASSESS-AKI) cohort studies. Using biomarkers that represent the multifactorial pathophysiology of CKD progression, we will be able to quantify the spectrum of kidney injury.

Contact Information

For more information, or if you are interested in collaborating on this study, please contact Dr. Jason Greenberg



Susan L. Furth, MD, PhD
Children's Hospital of Philadelphia

Prasad Devarajan, MD
Cincinnati Children's Hospital

Michael Zappitelli, MD, M.Sc.
The Hospital for Sick Children (Toronto, ON)